Ardigen is proud to announce its participation in the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium as a technology partner and collaborator. Through this role, Ardigen contributes its expertise in multi-modal data analysis—particularly in Cell Painting and related high-content imaging techniques—to support the development of innovative safety assessment tools in toxicology and drug development.
Convened in July 2023 by the Health and Environmental Sciences Institute (HESI) in collaboration with the Broad Institute of MIT and Harvard, and supported by the Massachusetts Life Sciences Center (MLSC), the OASIS Consortium brings together more than 60 global experts across academia, government, industry, and NGOs.
The initiative focuses on advancing multi-omics approaches—including Cell Painting, transcriptomics, and proteomics—to develop more predictive and scalable tools for chemical safety assessment, with hepatotoxicity as its initial area of application.
As a technology partner, Ardigen contributes its analytical capabilities and scientific insights to the consortium’s efforts. Our work complements a wide range of collaborators across disciplines working toward a shared goal: enabling earlier, more accurate understanding of toxicity profiles using systems biology.
Participation in the OASIS Consortium underscores Ardigen’s commitment to applying advanced AI and data science to improve translational research, reduce risk, and accelerate the development of safer therapies.
Disclaimer: Participation in the OASIS Consortium as a technology partner does not imply or constitute endorsement of Ardigen or its products and services by the OASIS Consortium, its funders, or any of its member organizations.
